Issue 41, 2021

Current progress, challenges and future prospects of indazoles as protein kinase inhibitors for the treatment of cancer

Abstract

The indazole core is an interesting pharmacophore due to its applications in medicinal chemistry. In the past few years, this moiety has been used for the synthesis of kinase inhibitors. Many researchers have demonstrated the use of indazole derivatives as specific kinase inhibitors, including tyrosine kinase and serine/threonine kinases. A number of anticancer drugs with an indazole core are commercially available, e.g. axitinib, linifanib, niraparib, and pazopanib. Indazole derivatives are applied for the targeted treatment of lung, breast, colon, and prostate cancers. In this review, we compile the current development of indazole derivatives as kinase inhibitors and their application as anticancer agents in the past five years.

Graphical abstract: Current progress, challenges and future prospects of indazoles as protein kinase inhibitors for the treatment of cancer

Article information

Article type
Review Article
Submitted
22 May 2021
Accepted
29 Jun 2021
First published
20 Jul 2021
This article is Open Access
Creative Commons BY license

RSC Adv., 2021,11, 25228-25257

Current progress, challenges and future prospects of indazoles as protein kinase inhibitors for the treatment of cancer

N. Tandon, V. Luxami, D. Kant, R. Tandon and K. Paul, RSC Adv., 2021, 11, 25228 DOI: 10.1039/D1RA03979B

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements